Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line

Cancer Research

Volumn 59, Issue 5, 1999, Pages 1021-1028

  Hazlehurst, Lori A ^a   Foley, Nils E ^a   Gleason Guzman, Mary C ^a   Hacker, Miles P ^c   Cress, Anne E ^b   Greenberger, Lee W ^d   De Jong, Mariska C ^a   Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c GRAND VALLEY STATE UNIVERSITY   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; MITOXANTRONE;

ARTICLE; CROSS RESISTANCE; DNA PROTEIN COMPLEX; DNA SYNTHESIS INHIBITION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LOCALIZATION; GENE TARGETING; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MYELOMA CELL; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL NUCLEUS; CELL SURVIVAL; CYTOPLASM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; KINETICS; MICROSCOPY, CONFOCAL; MITOXANTRONE; MULTIPLE MYELOMA; MYCOTOXINS; OUABAIN; TUMOR CELLS, CULTURED;

EID: 0033104367     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Smith, P. J., Morgan, S. A., Fox, M. E., and Watson, J. V. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell cell lung cancer cells. Biochem. Pharmacol., 40: 2069-2078, 1990.
2. Hazlehurst, L. A., Krapcho, A. P., and Hacker, M. P. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem. Pharmacol., 50: 1087-1094, 1995.
3. Kapuscinski, J., Darzynkiewicz, Z., Tranganos, F., and Melamed, M. R. Interactions of a new antitumor agent. 1,4-dihydroxy-5,8-bis[(2-[(2-hydroxyethyl)amino]ethyl]-amino-9,10- anthracenedione in nucleic acids. Biochem. Pharmacol., 30: 231-240, 1981.
4. Sutcliffe, J. A., Gootz, T. D., and Barret, J. F. Biochemical characteristics and physiological significance of major DNA topoisomerases. Antimicrob. Agents Chemother., 33: 2027-2033, 1989.
5. Dalton, W. S., Cress, A. E., Alberts, D. S., and Trent, J. M. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res., 48: 1882-1888, 1988.
6. Taylor, C. W., Dalton, W. S., Parrish, M. C., Gleason, M. C., Bellamy, W. T., Thompson, F. H., Roe, D. J., and Trent, J. M. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br. J. Cancer, 63: 923-929, 1991.
7. Futscher, B. W., Ahbaszadegan, M. R., Domann, F., and Dalton, W. S. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem. Pharmacol., 47: 1601-1606, 1994.
8. Nakagawa, M., Schneider, E., Dixon, K. H., Horton, J., Kelley, K., Marrow, C., and Cowan, K. H. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res., 52: 6175-6181, 1992.
9. Harker, G. W., Slade, D. L., Dalton, W. S., Meltzer, P. S., and Trent, J. M. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res., 49: 4542-4549, 1989.
10. Harker, W. G., Slade, D. L., Parr, R. L., and Holguin, M. H. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to truncated topoisomerase IIα messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res., 55: 4962-4971, 1995.
11. Dalton, W. S., Grogan, T. M., Rybski, J. A., Scheper, R. J., Richter, L., Kailey, J., Broxterman, H. J., Pinedo, H. M., and Salmon, S. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with levels of drug resistance and drug accumulation. Blood, 73: 747-752, 1989.
12. Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.
13. Sullivan, D. M., Glisson, B. S., Hodges, P. K., Smallwood-Kentro, S., and Ross W. E. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry, 25: 2248-2256, 1986.
14. Wolverton, J. S., Danks, M. K., Grazen, B., and Beck, W. T. DNA topoisomerase II immunostaining in human leukemia amd rhabdomysarcoma cell lines and their responses to topoisomerase II inhibitors. Cancer Res., 52: 4248-4253, 1992.
15. Danks, M. K., Qui, J., Captapano, C. V., Schmidt, C. A., Beck, W. T., and Fernandes, D. J. Subcellular distribution of the α and β topoisomerase II-DNA complexes stabilized by VM-26. Biochem. Pharmacol., 48: 1785-1795, 1994.
16. Slapak, C. A., Daniel, J. C., and Levy, S. B. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamyein selection: decreased anthracycline uptake precedes increased P-glycoprotein expression. Cancer Res., 50: 7895-7901, 1990.
17. Hurwitz, S. J., Terashima, M., Mizunuma, N., and Slapak, C. A. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes. Blood, 89: 3745-3754, 1997.
18. Slapak, C. A., Mizunuma, N., and Kufe, D. W. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood, 84: 3113-3121, 1994.
19. Yang, C. J., Horton, J. K., Cowan, K. H., and Schneider, E. Cross-resistance to camptothecin analoques in a mitoxantrone-resistant breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res., 55: 4004-4009, 1995.
20. Dietel, M., Arps, H., Lage, H., and Niendorf, A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res., 50: 6100-6106, 1990.
21. Slapak, C. A., Lecerf, J-M., Daniel, J. C., and Levy, S. B. Energy-dependent accumulation of daunorubicin into subcellular compartments of human leukemia cells and cytoplasts. J. Biol. Chem., 267: 10638-10644, 1992.
22. Schuurhuis, G. J., Broxterman, H. J., de Lange, J. H. M., Pinedo, H. M., van Heijningen, T. H. M., Kuiper, C. M., Scheffer, G. L., Scheper, R. J., van Kalken, C. K., Baak, J. P. A., and Lankelma, J. Early multidrug resistance, defined by changes in intracellular doxoruhicin distrihution, independent of P-glycoprotein. Br. J. Cancer. 64: 857-861, 1991.
23. Abbaszadegan, M. R., Cress, A. E., Futscher, B. W., Bellamy, W. T., and Dalton, W. S. Evidence for cytoplasmic P-glycoproiein location associated with increasing niultidrug resistance to chemosensitizers. Cancer Res., 56: 5435-5442, 1996.
24. 4 sub-lines with increasing adriamycin resistance. Int. J. Cancer, 61: 375-380, 1995.
25. Futscher, B. W., Gleason-Guzman, M., Meltzer, P. S., Sullivan, D. M., Folley, N. E., Bellamy, W. T., and Dalton, W. S. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int. J. Cancer. 66: 520-525, 1996.
26. Harker, G. W., Slade, D. L., Drake, F. H., and Parr, R. L. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II β isoform. Biochemistry, 30: 9953-9961, 1991.
27. Webb, C. D., Latham, M. D., Lock, R. B., and Sullivan, D. M. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res., 51: 6543-6549, 1991.
28. Bugg, B. Y., Danks, M. K., Beck, W. T., and Suttle, D. P. Expression of a mutant topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl. Acad. Sci. USA, 88: 7654-7658, 1991.
29. Yu, Q., Mirski, S. E., Sparks, K. E., and Cole, S. P. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing. Biochemistry, 36: 5868-5877, 1997.
30. 1 160,000 topoisomerase IIα is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res., 55: 2129-2134, 1995.
31. Feldhoff, P. W., Mirski, S. E., Cole, S. P., and Sullivan. D. M. Altered subcellular distribution of topoisomerase II α in a drug-resistant human small cell lung cancer cell line. Cancer Res., 54: 756-762, 1994.
32. 1492 in the COOH-terminal region of topoisomerase IIα in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res., 57: 4451-4454, 1997.
33. Harker, W. G., Slade, L. D., Parr, R. L., Feldhoff, P. W., Sullivan, D. M., and Holquin, M. H. Alterations in the topoisomerase IIα gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II β enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res., 55: 1707-1716, 1995.
34. Friche, E., Danks, M. K., Schmidt, C. A., and Beck, W. T. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res., 51: 4213-4218, 1991.
35. List, A. F., Spier, C., Greer, J., Wolf, S., Hutter, S., Dorr, R., Salmon, S., Futscher, B., Baier, M., and Dalton, W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol., II: 1652-1660, 1993.